Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Moderna Lost 29.6% in June

By Maxx Chatsko - Jul 9, 2019 at 2:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The post-IPO blues hit pretty hard last month.

What happened

Shares of Moderna (MRNA 3.78%) sank nearly 30% last month, according to data provided by S&P Global Market Intelligence. Two factors drove the stock price lower. 

First, the biopharma held its initial public offering (IPO) in early December, which means the customary 180-day lockup period in which employees cannot sell shares expired in early June. It appears employees unloaded at least some of their holdings when finally given the chance, according to Bloomberg.

Second, Moderna shared data from an ongoing phase 1 trial for one of its personalized cancer vaccines (PCV) at the 2019 American Society of Clinical Oncology (ASCO) meeting. The data were a little underwhelming, but mostly because they're still from very early studies in only a handful of patients. That left Wall Street wanting more. 

A chart on a chalk board showing steady gains and then a sudden loss.

Image source: Getty Images.

So what

Moderna raked in a biopharma-record $604 million in IPO proceeds in December, but shares have lost 21% in their first six months on the market. Despite the decline, the business sports a market valuation of about $5 billion. That's relatively healthy for a company that remains in the earliest stages of clinical development and reported a $141 million operating loss in the first quarter of 2019. 

Of course, that sour calculus could also be driving investors to reconsider the company's valuation. Moderna is developing PCVs based on editing RNA molecules. Your body, of course, has DNA, which contains the genetic code for creating RNA, which contains the genetic code for creating the various proteins that drive cellular function. When your DNA has an error in it, the wrong RNA is created, which means faulty proteins (read: disease and aging) arise. 

Moderna thinks that editing RNA molecules specific to a patient's disease or cancer and injecting them back into the patient could drive robust and durable responses to treatment by rallying the patient's immune system to attack damaged and mutated cells. The approach could work, but the recent emergence of gene editing and novel immunotherapies might make RNA editing a little outdated. 

After all, DNA is the ideal therapeutic target for editing, since it's further upstream from RNA and actually fixes the source of the genetic error. There's also a heightened risk of safety issues, since a single RNA molecule can serve multiple functions in the body. In other words, an experimental PCV could successfully target cancerous tumors but cause unacceptable side effects in the process.

Now what

At this point, investors simply need to see more robust data from Moderna. That might not come until the 2020 ASCO meeting, but that's the nature of investing in early-stage biopharma companies. The silver lining is that the business exited March with $1.1 billion in cash, cash equivalents, and investments, which means it has plenty of capital to weather steep operating losses as it treks toward more complete results to share with Wall Street.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$135.80 (3.78%) $4.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.